Infliximab as first-line therapy for Crohn's disease is premature

被引：0

作者：

Greenberg, GR ^{[1
]}

机构：

[1] Univ Toronto, Dept Med, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada

来源：

INFLAMMATORY BOWEL DISEASES | 2002年 / 8卷 / 01期

关键词：

D O I：

10.1097/00054725-200201000-00011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：60 / 62

页数：3

共 20 条

[1] A CONTROLLED DOUBLE-BLIND-STUDY OF AZATHIOPRINE IN THE MANAGEMENT OF CROHNS-DISEASE [J].

CANDY, S ;

WRIGHT, J ;

GERBER, M ;

ADAMS, G ;

GERIG, M ;

GOODMAN, R .

GUT, 1995, 37 (05) :674-678

[2] Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial [J].

D'Haens, G ;

Van Deventer, S ;

Van Hogezand, R ;

Chalmers, D ;

Kothe, C ;

Baert, F ;

Braakman, T ;

Schaible, T ;

Geboes, K ;

Rutgeerts, P .

GASTROENTEROLOGY, 1999, 116 (05) :1029-1034

[3] Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy [J].

Farrell, RJ ;

Alsahli, M ;

Falchuk, KR ;

Peppercorn, MA ;

Michetti, P .

GASTROENTEROLOGY, 2001, 120 (05) :A69-A69

[4] The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study [J].

Faubion, WA ;

Loftus, EV ;

Harmsen, WS ;

Zinsmeister, AR ;

Sandborn, WJ .

GASTROENTEROLOGY, 2001, 121 (02) :255-260

[5]

FEAGAN BG, 1995, NEW ENGL J MED, V332, P330

[6] Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study [J].

Greenberg, GR ;

Feagan, BG ;

Martin, F ;

Sutherland, LR ;

Thomson, ABR ;

Williams, N ;

Nilsson, LG ;

Persson, T .

GASTROENTEROLOGY, 1996, 110 (01) :45-51

[7] ORAL BUDESONIDE FOR ACTIVE CROHNS-DISEASE [J].

GREENBERG, GR ;

FEAGAN, BG ;

MARTIN, F ;

SUTHERLAND, LR ;

THOMSON, ABR ;

WILLIAMS, CR ;

NILSSON, LG ;

PERSSON, T ;

BAIN, V ;

CHERRY, R ;

FEDORAK, R ;

LALOR, E ;

SHERBANIUK, R ;

YACYSHYN, B ;

KIERDEKIS, P ;

BAILEY, R ;

MEYER, D ;

FREEMAN, H ;

DAWS, P ;

HOLLAND, S ;

BUYTENDORP, M ;

WHITTAKER, S ;

CHANG, A ;

SUTHERLAND, L ;

HERSHFIELD, N ;

MACCANNELL, K ;

MEDDING, J ;

PRICE, L ;

SHAFFER, E ;

RACICOT, N ;

BASS, S ;

BRIDGES, R ;

BLUSTEIN, P ;

LAY, T ;

VANROSENDAAL, G ;

WATSON, M ;

WILLIAMS, CN ;

VANZANTEN, V ;

LEDDIN, D ;

FALKENHAM, J ;

TANTON, R ;

HUMAN, P ;

TURNBALL, G ;

SCHEP, G ;

WOOLNOUGH, J ;

DALLAIRE, C ;

ROSSEAU, B ;

BERNARD, F ;

DUBE, R ;

PARE, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :836-841

[8] Maintenance infliximab (remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the ACCENT I trial. [J].

Hanauer, SB ;

Lichtenstein, GR ;

Columbel, JF ;

Mayer, L ;

Schreiber, S ;

Rachmilewicz, D ;

Wolf, D ;

Malchow, H ;

Safdi, M ;

Feagan, B ;

Olson, A ;

Rutgeerts, P .

GASTROENTEROLOGY, 2001, 120 (05) :A21-A21

[9]

MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249

[10] CLINICAL, BIOLOGICAL, AND ENDOSCOPIC PICTURE OF ATTACKS OF CROHNS-DISEASE - EVOLUTION ON PREDNISOLONE [J].

MODIGLIANI, R ;

MARY, JY ;

SIMON, JF ;

CORTOT, A ;

SOULE, JC ;

GENDRE, JP ;

RENE, E .

GASTROENTEROLOGY, 1990, 98 (04) :811-818

← 1 2 →